Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Bijo Mathew, Veerasamy Ravichandran, Seenivasan Raghuraman, T. M. Rangarajan, Mohamed A. Abdelgawad, Iqrar Ahmad, Harun M. Patel & Hoon Kim. (2023) Two dimensional-QSAR and molecular dynamics studies of a selected class of aldoxime- and hydroxy-functionalized chalcones as monoamine oxidase-B inhibitors. Journal of Biomolecular Structure and Dynamics 41:19, pages 9256-9266.
Read now
Read now
Julio Rea, M. D. García-Giménez, Marti Santiago, Rocío De la Puerta & M. A. Fernández-Arche. (2021) Hydroxycinnamic acid derivatives isolated from hempseed and their effects on central nervous system enzymes. International Journal of Food Sciences and Nutrition 72:2, pages 184-194.
Read now
Read now
Thomas Müller & Jan-Dominique Möhr. (2019) Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson’s disease: current status. Expert Opinion on Drug Metabolism & Toxicology 15:5, pages 429-435.
Read now
Read now
Daniela Secci, Simone Carradori, Anél Petzer, Paolo Guglielmi, Melissa D’Ascenzio, Paola Chimenti, Donatella Bagetta, Stefano Alcaro, Gokhan Zengin, Jacobus P. Petzer & Francesco Ortuso. (2019) 4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis. Journal of Enzyme Inhibition and Medicinal Chemistry 34:1, pages 597-612.
Read now
Read now
Thomas Müller. (2018) Safinamide: an add-on treatment for managing Parkinson’s disease. Clinical Pharmacology: Advances and Applications 10, pages 31-41.
Read now
Read now
Simone Carradori, Daniela Secci & Jacques P. Petzer. (2018) MAO inhibitors and their wider applications: a patent review. Expert Opinion on Therapeutic Patents 28:3, pages 211-226.
Read now
Read now
Thomas Müller. (2017) Valbenazine for the treatment of tardive dyskinesia. Expert Review of Neurotherapeutics 17:12, pages 1135-1144.
Read now
Read now
Thomas Müller. (2017) Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson’s disease. Expert Opinion on Pharmacotherapy 18:14, pages 1457-1465.
Read now
Read now
Thomas Müller. (2017) Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 13:6, pages 693-699.
Read now
Read now
Articles from other publishers (43)
Marika Alborghetti, Edoardo Bianchini, Lanfranco De Carolis, Silvia Galli, Francesco E. Pontieri & Domiziana Rinaldi. (2024) Type-B monoamine oxidase inhibitors in neurological diseases. Neural Regeneration Research 19:1, pages 16-21.
Crossref
Crossref
David Kolar, Branislav Krajcovic, Lenka Kleteckova, Daniela Kuncicka, Karel Vales & Hana Brozka. (2023) Review: Genes Involved in Mitochondrial Physiology Within 22q11.2 Deleted Region and Their Relevance to Schizophrenia. Schizophrenia Bulletin 49:6, pages 1637-1653.
Crossref
Crossref
Pradeep Paudel, Jae Sue Choi, Ritu Prajapati, Su Hui Seong, Se Eun Park, Woo-Chang Kang, Jong-Hoon Ryu & Hyun Ah Jung. (2023) In Vitro Human Monoamine Oxidase Inhibition and Human Dopamine D4 Receptor Antagonist Effect of Natural Flavonoids for Neuroprotection. International Journal of Molecular Sciences 24:21, pages 15859.
Crossref
Crossref
Emilio Mateev, Maya Georgieva, Alexandrina Mateeva, Alexander Zlatkov, Shaban Ahmad, Khalid Raza, Vasco Azevedo & Debmalya Barh. (2023) Structure-Based Design of Novel MAO-B Inhibitors: A Review. Molecules 28:12, pages 4814.
Crossref
Crossref
Naseer Maliyakkal, Iqrar Ahmad, Sunil Kumar, Sachithra Thazhathuveedu Sudevan, Asmy Appadath Beeran, Harun Patel, Hoon Kim & Bijo Mathew. (2023) A structural approach to investigate halogen substituted MAO-B inhibitors using QSAR modeling, molecular dynamics, and conceptual DFT analysis. Journal of Saudi Chemical Society, pages 101675.
Crossref
Crossref
Ming Sun, Chao Wu, Lixin Liu, Liang Gu, Zihao Wang, Feng Xu & Donglin Zhu. (2023) Interplay between the renin angiotensin system and oxidative stress contributes to alcohol addiction by stimulating dopamine accumulation in the mesolimbic pathway. Biochemical Pharmacology 212, pages 115578.
Crossref
Crossref
Ranju Bansal, Ranjit Singh & Pratibha Rana. (2023) Synthesis, in silico Studies and Pharmacological Evaluation of a New
Series of Indanone Derivatives as Anti-Parkinsonian and Anti-Alzheimer’s
Agents. Current Computer-Aided Drug Design 19:2, pages 94-107.
Crossref
Crossref
Vinitha Rani & Ashwini Prabhu. (2023) In vitro blood brain barrier models: Molecular aspects and therapeutic strategies in glioma management. Current Research in Translational Medicine 71:1, pages 103376.
Crossref
Crossref
Peter Riederer & Dan Rujescu. 2023. Discoveries in Pharmacology. Discoveries in Pharmacology
137
143
.
Mubashir Hassan, Aqsa Amir, Saba Shahzadi & Andrzej Kloczkowski. (2022) Therapeutic Implications of microRNAs in Depressive Disorders: A Review. International Journal of Molecular Sciences 23:21, pages 13530.
Crossref
Crossref
Ashi Mannan, Thakur Gurjeet Singh, Varinder Singh, Nikhil Garg, Amarjot Kaur & Manjinder Singh. (2022) Insights into the Mechanism of the Therapeutic Potential of Herbal
Monoamine Oxidase Inhibitors in Neurological Diseases. Current Drug Targets 23:3, pages 286-310.
Crossref
Crossref
Jeffrey H. Meyer, Dmitriy Matveychuk, Andrew Holt, Apitharani Santhirakumar & Glen B. Baker. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1347
1379
.
Thomas Müller. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
2853
2870
.
O. S. Egorov, N. Yu. Borisova, E. Ya. Borisova, M. L. Rezhabbaev, E. Yu. Afanas’eva & E. V. Arzamastsev. (2021) Structure and biological action of analogs and derivatives of biogenic polyamines. Fine Chemical Technologies 16:4, pages 287-306.
Crossref
Crossref
Sunil Kumar, Aathira Sujathan Nair, Vaishnav Bhashkar, Sachithra Thazhathuveedu Sudevan, Vishal Payyalot Koyiparambath, Ahmed Khames, Mohamed A. Abdelgawad & Bijo Mathew. (2021) Navigating into the Chemical Space of Monoamine Oxidase Inhibitors by Artificial Intelligence and Cheminformatics Approach. ACS Omega 6:36, pages 23399-23411.
Crossref
Crossref
Daniela Silva-Adaya, Carla Garza-Lombó & María E. Gonsebatt. (2021) Xenobiotic transport and metabolism in the human brain. NeuroToxicology 86, pages 125-138.
Crossref
Crossref
Haiyan Kong, Xianshe Meng, Rui Hou, Xiaoxiao Yang, Jihong Han, Zhouling Xie, Yajun Duan & Chenzhong Liao. (2021) Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation. Bioorganic & Medicinal Chemistry Letters 43, pages 128051.
Crossref
Crossref
Vishal Payyalot Vishal, Jong Min Oh, Ahmed Khames, Mohamed A. Abdelgawad, Aathira Sujathan Nair, Lekshmi R. Nath, Nicola Gambacorta, Fulvio Ciriaco, Orazio Nicolotti, Hoon Kim & Bijo Mathew. (2021) Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders. Pharmaceutics 13:6, pages 850.
Crossref
Crossref
Jeffrey H. Meyer, Dmitriy Matveychuk, Andrew Holt, Apitharani Santhirakumar & Glen B. Baker. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
33
.
Jakub Pobłocki, Anna Jasińska, Anhelli Syrenicz, Elżbieta Andrysiak-Mamos & Małgorzata Szczuko. (2020) The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition. Nutrients 12:5, pages 1437.
Crossref
Crossref
Anamaria Bogdan, Valeria Manera, Alexandra Koenig & Renaud David. (2020) Pharmacologic Approaches for the Management of Apathy in Neurodegenerative Disorders. Frontiers in Pharmacology 10.
Crossref
Crossref
Thomas Müller. 2019. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
18
.
Muhammet Serhat Özaslan, Neslihan Balcı, Yeliz Demir, Mahmut Gürbüz & Ömer İrfan Küfrevioğlu. (2019) Inhibition effects of some antidepressant drugs on pentose phosphate pathway enzymes. Environmental Toxicology and Pharmacology 72, pages 103244.
Crossref
Crossref
Federico Tasca, Angelica Fierro & Gilbert Nöll. (2019) Spectroelectrochemical study revealing the redox potential of human monoamine oxidase A. Electrochimica Acta 317, pages 612-617.
Crossref
Crossref
Edidiong N. Akang, Olufunke O. Dosumu, Olasunmbo O. Afolayan, Adeola M. Fagoroye, Daniel D. Osiagwu, Isilamiyat T. Usman, Ademola A. Oremosu & Alani S. Akanmu. (2019) Combination antiretroviral therapy (cART)-induced hippocampal disorders: Highlights on therapeutic potential of Naringenin and Quercetin. IBRO Reports 6, pages 137-146.
Crossref
Crossref
Ankur Butala, Melissa Shepard & Greg Pontone. 2019. Psychopharmacology of Neurologic Disease. Psychopharmacology of Neurologic Disease
83
121
.
Bijo Mathew, Seung Cheol Baek, Della Grace Thomas Parambi, Jae Pil Lee, Monu Joy, P. R. Annie Rilda, Rugma V. Randev, P. Nithyamol, Vijitha Vijayan, Sini T. Inasu, Githa Elizabeth Mathew, Krishnakumar K. Lohidakshan, Girish Kumar Krishnan & Hoon Kim. (2018) Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors. MedChemComm 9:11, pages 1871-1881.
Crossref
Crossref
Luca Giacinto Iacovino, Francesca Magnani & Claudia Binda. (2018) The structure of monoamine oxidases: past, present, and future. Journal of Neural Transmission 125:11, pages 1567-1579.
Crossref
Crossref
Rani Sasidharan, Seung Cheol Baek, Manju Sreedharannair Leelabaiamma, Hoon Kim & Bijo Mathew. (2018) Imidazole bearing chalcones as a new class of monoamine oxidase inhibitors. Biomedicine & Pharmacotherapy 106, pages 8-13.
Crossref
Crossref
Jasim Khan, Shikha Salhotra, Shahzad Ahmad, Shikha Sharma, Sayed Aliul Hasan Abdi, Basu Dev Banerjee, Suhel Parvez, Sarika Gupta & Sheikh Raisuddin. (2018) The protective effect of α-lipoic acid against bisphenol A-induced neurobehavioral toxicity. Neurochemistry International 118, pages 166-175.
Crossref
Crossref
Ronan Gealageas, Alice Devineau, Pauline P. L. So, Catrina M. J. Kim, Jayakumar Surendradoss, Christian Buchwalder, Markus Heller, Verena Goebeler, Edith M. Dullaghan, David S. Grierson & Edward E. Putnins. (2018) Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood–Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases. Journal of Medicinal Chemistry 61:16, pages 7043-7064.
Crossref
Crossref
Maa O. Quartey, Jennifer N. K. Nyarko, Paul R. Pennington, Ryan M. Heistad, Paula C. Klassen, Glen B. Baker & Darrell D. Mousseau. (2018) Alzheimer Disease and Selected Risk Factors Disrupt a Co-regulation of Monoamine Oxidase-A/B in the Hippocampus, but Not in the Cortex. Frontiers in Neuroscience 12.
Crossref
Crossref
Margaret (Mandy) R. MacLean. (2018) The serotonin hypothesis in pulmonary hypertension revisited: targets for novel therapies (2017 Grover Conference Series). Pulmonary Circulation 8:2, pages 1-9.
Crossref
Crossref
Zhanna V. Chirkova, Mariya V. Kabanova, Sergey I. Filimonov, Igor G. Abramov, Anél Petzer, Idalet Engelbrecht, Jacobus P. Petzer, Kyrill Yu Suponitsky & Alexander V. Veselovsky. (2018)
An investigation of the monoamine oxidase inhibition properties of pyrrolo[3,4-
f
]indole-5,7-dione and indole-5,6-dicarbonitrile derivatives
. Drug Development Research 79:2, pages 81-93.
Crossref
Crossref
Xuan Xiao, Xing-Xing Zhang, Mei-Miao Zhan, Kai Cheng, Shiyu Li, Zhouling Xie & Chenzhong Liao. (2018) Design, synthesis and bioevalucation of novel 2,3-dihydro-1 H -inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline. European Journal of Medicinal Chemistry 145, pages 588-593.
Crossref
Crossref
Al-Shimali M. Hussain, Waleed M. Renno, Hanaa L. Sadek, Noura M. Kayali, Aseel Al-Salem, Muddanna S. Rao & Khalid M. Khan. (2018) Monoamine oxidase-B inhibitor protects degenerating spinal neurons, enhances nerve regeneration and functional recovery in sciatic nerve crush injury model. Neuropharmacology 128, pages 231-243.
Crossref
Crossref
George Anderson & Michael Maes. 2018. Inflammation and Immunity in Depression. Inflammation and Immunity in Depression
549
567
.
Makoto Naoi, Wakako Maruyama & Masayo Shamoto-Nagai. (2017) Type A monoamine oxidase and serotonin are coordinately involved in depressive disorders: from neurotransmitter imbalance to impaired neurogenesis. Journal of Neural Transmission 125:1, pages 53-66.
Crossref
Crossref
Carlo Cattaneo, Thomas Müller, Erminio Bonizzoni, Gabriele Lazzeri, Ioannis Kottakis & Charlotte Keywood. (2017) Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson’s Disease. Journal of Parkinson's Disease 7:4, pages 629-634.
Crossref
Crossref
Thomas MüllerPeter RiedererEdna Grünblatt. (2017) Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease. Clinical Neuropharmacology 40:5, pages 208-211.
Crossref
Crossref
Ian Cook, Ting Wang & Thomas S. Leyh. (2017) Tetrahydrobiopterin regulates monoamine neurotransmitter sulfonation. Proceedings of the National Academy of Sciences 114:27.
Crossref
Crossref
Thomas Müller, Peter Riederer & Edna Grünblatt. (2017) Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson’s disease. Journal of Neural Transmission 124:6, pages 745-748.
Crossref
Crossref
Lucian Hritcu, Radu Ionita, Paula Alexandra Postu, Girish Kumar Gupta, Hasan Turkez, Tamires Cardoso Lima, Caroline Uchôa Souza Carvalho & Damião Pergentino de Sousa. (2017) Antidepressant Flavonoids and Their Relationship with Oxidative Stress. Oxidative Medicine and Cellular Longevity 2017, pages 1-18.
Crossref
Crossref